Evidence map›Paper›PMID 31640747›Full record

ArticleBreast cancer research : BCR2019

Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer.

Agnieszka Morgenroth, Ebru Tinkir, Andreas T J Vogg, Ramya Ambur Sankaranarayanan, Fatima Baazaoui, Felix M Mottaghy

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Theranostics in breast cancer.Frontiers in nuclear medicine · 2023
    Review
  15. Review
  16. Review
  17. PSMA-targeted theranostics of solid tumors: applications beyond prostate cancers.European journal of nuclear medicine and molecular imaging · 2022
    Article
  18. Article
  19. Review
  20. Non-invasive molecular imaging of kidney diseases.Nature reviews. Nephrology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Agnieszka MorgenrothDepartment of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany. amorgenroth@ukaachen.de.
Ebru TinkirDepartment of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany.
Andreas T J VoggDepartment of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany.
Ramya Ambur SankaranarayananDepartment of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany.
Fatima BaazaouiDepartment of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany.
Felix M MottaghyDepartment of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, Pauwelsstrasse 30, 52074, Aachen, Germany.
RWTH Aachen University · DEUniversitätsklinikum Aachen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTriple-negative breast cancer has extremely high risk of relapse due to the lack of targeted therapies, intra- and inter-tumoral heterogeneity, and the inherent and acquired resistance to therapies. In this study, we evaluate the potential of prostate-specific membrane antigen (PSMA) as target for radio-ligand therapy (RLT).

methodsTube formation was investigated after incubation of endothelial HUVEC cells in tumor-conditioned media and monitored after staining using microscopy. A binding study with

resultsThe triple-negative breast cancer cells MDA-MB231 showed a high pro-angiogenetic potential on tube formation of endothelial HUVEC cells. The induced endothelial expression of PSMA was efficiently addressed by radiolabeled PSMA-specific ligands.

conclusionsHere we demonstrate PSMA as promising target for two-compartment endogenous radio-ligand therapy of triple-negative breast cancer.

Indexed as

AnimalsAntigens, SurfaceBlood VesselsCell Line, TumorCulture Media, ConditionedDipeptidesEdetic AcidGallium IsotopesGallium RadioisotopesGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingHumansHuman Umbilical Vein Endothelial CellsLigandsLutetiumMCF-7 CellsAntigens, SurfaceCulture Media, ConditionedDipeptidesEdetic AcidFOLH1 protein, humangallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingLigandsLutetiumLutetium-177OligopeptidesPluvictoProstate-Specific AntigenRadioisotopesRadiopharmaceuticalsProstate-specific membrane antigenRadio-ligand therapyTriple-negative breast cancer

Identifiers

PMID31640747
PMCPMC6805467
OpenAlexW2981440959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.